Related Experiment Videos
Topical ketoconazole for infantile seborrhoeic dermatitis
A Taieb1, V Legrain, C Palmier
1Service de Dermatologie Pédiatrique, Hôpital des Enfants, Bordeaux, France.
Insights
Ketoconazole 2% cream effectively treated seborrhoeic rash in infants, with minimal absorption and no accumulation. Most infants showed significant improvement within 10 days.
Area of Science:
- Dermatology
- Pediatrics
- Pharmacology
Background:
- Seborrhoeic dermatitis is a common inflammatory skin condition in infants.
- Topical antifungal agents are a primary treatment modality.
Purpose of the Study:
- To evaluate the efficacy and safety of ketoconazole 2% cream for infant seborrhoeic dermatitis.
- To assess percutaneous absorption and plasma accumulation of ketoconazole.
Main Methods:
- An open-label study involving 19 infants with bipolar seborrhoeic rash.
- Daily application of ketoconazole 2% cream for 10 days.
- Evaluation of clinical improvement, percutaneous absorption, and plasma ketoconazole levels.
Main Results:
- 78.9% of infants achieved near-complete clearance of rash by day 10.
- Minimal percutaneous absorption of ketoconazole was observed.
- No detectable plasma ketoconazole accumulation occurred over the treatment period.
Conclusions:
- Ketoconazole 2% cream is an effective and safe topical treatment for infant seborrhoeic dermatitis.
- Treatment failures were associated with psoriasiform eruptions and probable atopic dermatitis.
- Minimal systemic absorption supports its use in pediatric populations.
Abstract:
In an open study, 19 infants with a bipolar seborrhoeic rash were treated with ketoconazole 2% in cream once a day and evaluated over 10 days of treatment. At day 10, 78.9% of patients were almost cleared. Percutaneous absorption peaked 1-3 h after topical treatment, and was minimal. No plasma ketoconazole accumulation over the 10-day treatment was detected. Treatment failures corresponded to histologically psoriasiform eruptions and probable atopic dermatitis.